GIO Therapeutics
Xavier Leroy, PhD, is a seasoned executive with extensive experience in biotechnology and pharmaceuticals. Currently serving as Chief Executive Officer at GIO Therapeutics and Founder & CEO at Ankyo, Xavier also holds the role of Executive in Residence at Cumulus Oncology and President at the Biodiversity Heritage Site « Jean & Marie-Claire Leroy ». With a robust background in scientific leadership, Xavier has previously worked as Chief Scientific Officer at Domain Therapeutics and Chief Technology Officer at iTeos Therapeutics SA, among other notable positions. Educational credentials include a PhD in Biology & Pharmacology from Université de Bretagne Occidentale and an Executive MBA from HEC Paris. Xavier has actively contributed to various European research networks and has significant expertise in drug discovery and project leadership within renowned organizations.
This person is not in any teams
This person is not in any offices
GIO Therapeutics
GIO Therapeutics stands at the forefront of medical innovation, specialising in the development of G protein-coupled receptor (GPCR)-targeted pharmaceuticals. Recent scientific research has highlighted the crucial role of GPCRs as membrane receptors within the tumour microenvironment where their role significantly impacts intercellular signalling. This discovery has produced a new pool of potential therapeutic targets, which are now becoming accessible thanks to advanced structure-based drug design techniques. Our innovative approach positions us to address complex challenges in oncology and inflammatory diseases. Each member of the GIO team brings a unique set of skills and experiences, all united by a shared passion for drug discovery and a history of building and creating successful companies. At GIO Therapeutics, we believe in the power of collaboration to drive innovation and achieve groundbreaking results in oncology. We welcome like-minded organisation and professionals to get in touch. GIO Therapeutics is a proud venture of Cumulus Oncology.